Hotelaria de longevidade para além do retiro de luxo

The next decade of longevity is not going to be won at USD 50,000 a week.

For most of the last cycle, our category leaned into ever more elaborate retreat pricing. Beautiful architecture, world-class clinicians, USD 30k to 80k programs. The math works for a narrow global cohort. It does not work for the category.

Three things have shifted quietly while we were building flagships:

• A comprehensive longevity blood panel that ran USD 3,000 in 2018 now lands under USD 400. - Whole genome sequencing has dropped from five figures to roughly USD 200. - Continuous glucose, sleep, HRV, and recovery data now live on the guest's wrist before they ever check in.

The unit economics of evidence-based longevity have shifted by an order of magnitude. The science has only gotten sharper. The infrastructure got cheaper, and the AI interpretation layer is essentially free.

The bottleneck is no longer cost. It is the operating model.

The question I am putting to capital partners and hotel groups right now is the one almost no one is publishing on: what does a regenerative longevity layer look like as a recurring monthly experience inside a residential or hospitality footprint, priced for the upper-middle tier rather than the ultra-wealthy? What does a USD 1,500 a month membership unlock when the diagnostic cost basis has collapsed?

That is where the category's next decade lives. Not in the price ceiling. In the floor we choose to build.

Curious to hear from operators and developers thinking about this layer.